Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?

Expert Opin Drug Saf. 2016 Oct;15(10):1295-300. doi: 10.1080/14740338.2016.1201061. Epub 2016 Jul 5.

Authors

Stefania Oliva¹, Antonio Palumbo¹

Affiliation

¹ a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

PMID: 27351375
DOI: 10.1080/14740338.2016.1201061

No abstract available

Keywords: Multiple myeloma; daratumumab; elotuzumab; monoclonal antibodies; safety.

MeSH terms

ADP-ribosyl Cyclase 1 / immunology
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Drug Design*
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Signaling Lymphocytic Activation Molecule Family / immunology

Substances

Antibodies, Monoclonal
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family
ADP-ribosyl Cyclase 1